Compare Eli Lilly And Co (LLY) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs VICI Properties Inc — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while VICI Properties Inc trades at $22.92 (market cap $25.09B). The key difference: Eli Lilly And Co is far larger — about 41.5× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (8.07%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and VICI Properties Inc for 43 Days on average.
| LLY | VICI | |
|---|---|---|
Market Cap | $1.04T | $25.09B |
Volume | 3,064,878 | 17,066,337 |
Sector | Health | Real Estate |
52-Week High | $1.28K | $31.42 |
52-Week Low | $799.57 | $22.53 |
Typical Hold Time | 93 Days | 43 Days |
Enterprise Value | $1.09T | $42.65B |
Dividend Yield | 0.59% | 8.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
VICI Properties trades at $22.88, down 1.06% with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and attractive valuation at 8.83 P/E. The stock shows mixed earnings performance with recent misses but maintains robust cash flow and dividend coverage. Recent news highlights tenant diversification through new leases while addressing market concerns about regional casino exposure and rising interest rates.
The investment case balances deep value metrics against sector headwinds, with analyst consensus strongly bullish ($28.90 target) but technical weakness suggesting near-term pressure. Key opportunities include the 7.8% dividend yield with 1.3x coverage, while risks center on tenant concentration and interest rate sensitivity in the REIT structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
